Next-generation "molecular glue" degrader · relapsed/refractory multiple myeloma Phase III clinical trial
Official protocol title:A Phase 3, 2-Stage, Randomized, Multicenter, Open-label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM): SUCCESSOR-1
Trial Summary
This project is a Phase III clinical trial sponsored by Bristol Myers Squibb (BMS)/Celgene, primarily targeting patients with relapsed or refractory multiple myeloma (RRMM) who have received 1 to 3 prior lines of anti-myeloma therapy (which must have included lenalidomide). The treatment regimen consists of a novel immunomodulatory agent/CELMoD targeted drug (mezigdomide/CC-92480) combined with a proteasome inhibitor (bortezomib) and a corticosteroid (dexamethasone), administered in 21-day cycles. The control group receives pomalidomide combined with bortezomib and dexamethasone, with treatment continuing until disease progression or unacceptable toxicity. The trial is being conducted across 32 top domestic hospitals in China, including Beijing Chao-Yang Hospital Capital Medical University (East Campus), Peking University First Hospital, Sun Yat-sen University Cancer Center, Union Hospital Tongji Medical College of Huazhong University of Science and Technology, and Shanghai Sixth People's Hospital, while concurrently ongoing at 131 top international medical centers across 22 countries, including the United States, Canada, France, Australia, and the United Kingdom.
Participating Centers1 in China + 31 overseas
Source and Verification
Every fact on this page is derived from the official study protocol document below. The source document is archived as a PDF for direct verification.
- Document type
- CDE clinical trial registration filing (original PDF)
- Official registration number
- CTR20223338
- Verify on the NMPA CDE public platformby entering CTR20223338 in the registration-number field. The platform is a search interface with no permanent per-study URL, so a direct link is not possible.
- Last reconciled
- 2026-09-07
Frequently Asked Questions about this Study
Structured facts derived from official protocol filings for patient and family reference
According to official protocol filings (target population synthesized by CMDN from study details, not an official CDE field), this study is primarily designed for patients with [Relapsed/refractory]. Eligibility requires verified clinical confirmation by investigators regarding prior lines of therapy, active disease biomarkers, and performance status.
According to verified protocol filings, key eligibility thresholds include: age ≥ 18 years, ECOG performance status ≤ 2, 1–3 prior lines of therapy. The study specifies 14 inclusion and 23 exclusion criteria covering detailed organ function and medical history. Final enrollment confirmation is determined by investigators at participating hospital trial centers.
The core therapeutic target or investigational mechanism is [Next-generation "molecular glue" degrader (CELMoD)]. It aims to selectively eradicate clonal plasma cells or redirect anti-tumor immune responses, representing an active area of precision hematology research.
This study is registered as a [Phase III] clinical trial. The protocol is conducted under rigorous ethical and Good Clinical Practice (GCP) oversight approved by institutional ethics committees.
This is an international multi-centre study with 1 study centres in China and 31 overseas centres. The lead institution is [Beijing Chao-Yang Hospital, Capital Medical University (East Campus)]. Prominent sites include Beijing Chao-Yang Hospital, Capital Medical University (East Campus), Xi'an International Medical Center Co., Ltd., Peking University First Hospital, among others. Eligible domestic patients can seek screening at the nearest participating centre.
The official public registration identifier for this protocol is [CTR20223338] (CDE_CTR). Patients and researchers can verify registration details and regulatory authorizations directly on the official NMPA CDE platform.
Key Information
Status
Recruiting
Phase
Phase III
Target / Therapy
Next-generation "molecular glue" degrader (CELMoD)
Sponsor
Bristol-Myers Squibb (China) Investment Co., Ltd.
Principal Investigator
Wenming Chen
Lead Institution
Beijing Chao-Yang Hospital, Capital Medical University (East Campus)
Participating Centers
1 in China + 31 overseas
CDE Registry ID
CTR20223338
ClinicalTrials.gov ID
NCT05552976Trial information is translated from the Chinese source record and reviewed by CMDN. Confirm current status and eligibility with the study team.
Where this study sits in the landscape
Browse comparable active studies by disease stage, modality and province
Keywords
Considering a non-trial option?
International participation must be confirmed directly with the study team. If a clinical trial is not practical, review our independent guide to CAR-T in China.
View CAR-T in China Guide →Evidence · Process · Costs · Verified hospitals
Protocol drugs and related tests are fully covered by the sponsor. All studies are strictly supervised by ethics committees, and patients retain the legal right to withdraw at any time.
Read application guide & patient rights